Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Potential Alzheimer's Disease drugs under investigation

What to do when an Asthma Attack happens? Harward Medical School guide gives you step by step instructions.



22 August, 2005: Scientists are investigating a class of pharmaceuticals that may well improve memory function, including those with Alzheimer's disease, and address some of the underlying causes of memory loss rather than today's drugs that simply treat symptoms.

Cortex Pharmaceuticals is testing and developing a second-generation class of pharmaceuticals classified as ampakine compounds. Its lead compound, CX-717, is expected to treat the memory and thinking disorders associated with Mild Cognitive Impairment, and Alzheimer's disease as well as other disorders. It is believed that loss of connections between brain cells is responsible for memory loss. Ampakine compounds are said to increase the signal strength at those connections. (See http://www.cortexpharm.com/ for more detail.)

Ampakines are designed to compensate for deterioration of AMPA-receptor mediated brain activity in patients with Alzheimer's and other disorders. Ampakines may also increase the amount of certain growth factors in the brain, which, in turn, may help treat the underlying causes of conditions like Alzheimer's disease.

"We believe our drugs can be disease modifying therapies in contrast to the currently available symptomatic treatments," says Dr. Roger Stoll, the CEO of Cortex Pharmaceuticals.

Cortex Pharmaceuticals also recently announced that it began enrollment in the second and third AMPAKINE(R) CX717 Phase IIa studies: one in Attention Deficit Hyperactivity Disorder (ADHD) and the other in mild to moderate Alzheimer's disease (AD).

Alzheimer's disease is a gradually progressive brain disorder that causes memory loss, cognitive dysfunction, behavioral disturbances, and loss of the ability to take care of daily activities. Though the disease progresses at different rates in different people, in its severe stages most sufferers require total care for their needs.

Alzheimer's disease is the leading cause of adult-onset dementia. It currently affects one in 10 individuals over 65 and nearly half of those over 85. The disorder is one of the single greatest threats to the health of 77 million baby boomers and is also one of their greatest fears of aging. In the US alone, the cost of caring for individuals with Alzheimer's disease is estimated to be $100 billion annually.


Pharma News Headlines

Cancer News

Cardiac News


Pharma industry news

Diseases - Alzheimer's, Parkisonson's and Obesity

Contraception and Abortion News


Anti fungal terbinafine launched in Europe: Actavis

HIV entry blocking drug data encouraging: Progenics

Allegra generic to be launched in US

Long-acting pain drug data positive: Pain Therapeutics

New kidney cancer drug seeks EU nod

Inhaled insulin may get US FDA clearance

A vaccine against fungus is on way

Enzyme stops progression of HIV in survivors, confirms study

Aclasta found faster-acting in Paget's disease treatment

Beta blocker can start therapy in heart failure: Merck

Halobetasol generic launched in US

Anemia drug darbepoetin's late-stage studies begin: Amgen

Cholesterol generic gets marketing nod in US: Par

Aricept for severe Alzheimer’s disease too: Eisai

Bone regeneration trials begin in US:Mesoblast

New dye to detect early Alzheimer's

Breast forming gene discovered

Thyroid drug to be supplied by IVAX in US

Rituxan, cancer drug can treat rheumatoid arthritis

Yasminelle, low-dose oral contraceptive approved in the Netherlands

Fluarix, anti-flu shot by Glaxo approved

Increlex, drug to treat `abnormally short’ kids approved in US

Anti-HIV drugs prices cut: Gilead

US FDA approves Takeda’s drug combo for type 2 diabetes

Novartis’ drug for breast cancer recurrence to be given priority review in US

US puts off decision on contraceptive pill again

Shire’s ADHD drug Adderall back on list in Canada

WHO calls for emergency action to halt TB in Africa

Some of the Vioxx suits may be settled: Merck

Nasdaq delists Able on bankruptcy filing

Hospira ships ceftriaxone generics to US

Renovis stops sciatica drug studies

Merck sets up generic arm Genpharm in US

Morning after pills still not within easy reach in US

New cancer combo therapy results positive:OXiGENE

Aceon approved for heart disease treatment in US

Cell Therapeutics to seek approval for lung cancer therapy in US and Europe

Anti-depressant Seroxat defended by GSK against new findings

Vioxx verdict: Merck’s defeat to trigger thousands of lawsuits from US, UK

Aspirin stops colon cancer, but may trigger bleeding

New blood test method approved in US

Skin disease drug turns into anti-tumor therapy for cancer

Step-by-Step instructions for dealing with Asthma Attacks

Potential Alzheimer's Disease drugs under investigation

New Molecule may help obese lose weight

Paxil (Paroxetine) may heighten suicide risks, finds study

"Breast cancer chances higher due to fried chips"

Safety alert on Gambro Dasco’s Prisma renal system

Merck responsible for Vioxx death: Jury

Heart disease deaths more among New Yorkers

Pfizer to offer drugs risk/benefit summary to consumers 

Merck lied to public on Vioxx: lawyer tells jurors

Novartis acquires rights of kidney dialysis drug from SeBo

J&J's Concerta approved treatment of ADHD in teenagers in Canada

US FDA stalls Roche’ Accutane use in pregnancy

Novo Nordisk, Eli Lilly remove insulin products from Australia

British drug supply chain safety questioned after another fake Lipitor find

Wyeth starts support programme for Effexor patients

P&G’s Actonel with Calcium approved for osteoporosis

Pozen gets patent on pain management product

Genmab studies new drug for rheumatoid arthritis

Painkillers may increase blood pressure: study

Nektar buys out Aerogen for $32 m

Predix records positive data on anxiety drug

Insmed files against Increlex approval

Hepatitis A vaccine for kids approved in US

Psoriasis drug data positive: Cytochroma

Novo Nordisk’s 24-hour acting insulin Levemir gets US FDA okay

US FDA approves Teva's generic for osteoporosis 


Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us